Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Cannabidiol  COVID-19 treatment studies for Cannabidiol  C19 studies: Cannabidiol  Cannabidiol   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization -557% Improvement Relative Risk Recovery time -33% Crippa et al. Cannabidiol for COVID-19 RCT LATE TREATMENT Favors cannabidiol Favors control
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Crippa et al., Cannabis and Cannabinoid Research, doi:10.1089/can.2021.0093
Crippa et al., Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized,.., Cannabis and Cannabinoid Research, doi:10.1089/can.2021.0093
Oct 2021   Source   PDF  
  All Studies   Meta
RCT 105 patients recruited in an ER in Brazil, 49 treated with CBD, showing no significant differences with treatment. 300mg CBD for 14 days.
For discussion see [].
risk of hospitalization, 557.1% higher, RR 6.57, p = 0.25, treatment 3 of 49 (6.1%), control 0 of 42 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
recovery time, 33.3% higher, relative time 1.33, p = 0.20, treatment 49, control 42.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Crippa et al., 7 Oct 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Brazil, peer-reviewed, 32 authors, study period 7 July, 2020 - 16 October, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Abstract: Cannabis and Cannabinoid Research Volume X, Number X, 2021 ª Mary Ann Liebert, Inc. DOI: 10.1089/can.2021.0093 Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial José Alexandre S. Crippa,1,2,*,i Julia Cozar Pacheco,1 Antonio W. Zuardi,1,2 Francisco S. Guimarães,2,3 Alline Cristina Campos,3 Flávia de Lima Osório,1,2 Sonia Regina Loureiro,1 Rafael G. dos Santos,1,2 José Diogo S. Souza,1 Juliana Mayumi Ushirohira,1 Rafael Rinaldi Ferreira,3 Karla Cristinne Mancini Costa,3 Davi Silveira Scomparin,3 Franciele Franco Scarante,3 Isabela Pires-Dos-Santos,3 Raphael Mechoulam,4 Flávio Kapczinski,2,5,6 Benedito A.L. Fonseca,7 Danillo L.A. Esposito,7 Afonso Dinis Costa Passos,8 Amaury Lelis Dal Fabbro,8 Fernando Bellissimo-Rodrigues,8 Eurico Arruda,9 Sandro Scarpelini,10 Maristela Haddad Andraus,11 Julio Cesar Nather Junior,12 Danilo Tadao Wada,12 Marcel Koenigkam-Santos,12 Antonio Carlos Santos,12 Geraldo Busatto Filho,13 and Jaime E.C. Hallak1,2; for the Cannabidiol for COVID-19 Patients (CANDIDATE) Trial Investigators Abstract Importance: Owing to its anti-inflammatory properties and antiviral ‘‘in vitro’’ effect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cannabidiol (CBD) has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19). Objective: To investigate the safety and efficacy of CBD for treating patients with mild to moderate COVID-19. Design: Randomized, parallel-group, double-blind, placebo-controlled clinical trial conducted between July 7 and October 16, 2020, in two sites in Brazil. Setting: Patients were recruited in an emergency room. Participants: Block randomized patients (1:1 allocation ratio—by a researcher not directly involved in data collection) with mild and moderate COVID-19 living in Ribeirão Preto, Brazil, seeking medical consultation, and those who voluntarily agreed to participate in the study. Interventions: Patients received 300 mg of CBD or placebo added to standard symptomatic care during 14 days. Main Outcome and Measure: The primary outcome was reduction or prevention of the deterioration in clinical status from mild/moderate to severe/critical measured with the COVID-19 Scale or the natural course of the resolution of typical clinical symptoms. Primary study outcome was assessed on days 14, 21, and 28 after enrollment. Results: A total of 321 patients were recruited and assessed for eligibility, and 105 were randomly allocated either in CBD (n = 49) or in placebo (n = 42) group. Ninety-one participants were included in the analysis of efficacy. There were no baseline between-group differences regarding disease severity (v2 = 0.025, p = 0.988) and median time to symptom resolution (12 days [95% confidence interval, CI, 6.5–17.5] in the CBD group, 9 days [95% CI, 1 Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. National Institute for Science and Technology—Translational Medicine, São Paulo, Brazil. 3 Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. 4 Department of Medicinal Chemistry and Natural Products, The Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel. 5 Department of Psychiatry and..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop